^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TVI-Brain-1
i
Other names: TVI-Brain-1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
TVAX Biomedical
Drug class:
Immunostimulant
Related drugs:
1year
TVI-AST-008: Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2/3, N=120, Active, not recruiting, TVAX Biomedical | Suspended --> Active, not recruiting
Enrollment closed
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
over1year
TVI-AST-008: Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2/3, N=120, Suspended, TVAX Biomedical | Recruiting --> Suspended
Trial suspension
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
2years
TVI-AST-008: Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2/3, N=120, Recruiting, TVAX Biomedical | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
over2years
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2/3, N=96, Recruiting, TVAX Biomedical
Trial completion date • Trial primary completion date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
over2years
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2/3, N=96, Recruiting, TVAX Biomedical | Phase classification: P2b --> P2/3
Phase classification
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
almost3years
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2b, N=96, Recruiting, TVAX Biomedical | Not yet recruiting --> Recruiting
Enrollment open
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
almost3years
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2b, N=96, Not yet recruiting, TVAX Biomedical | Initiation date: Jun 2023 --> Sep 2023
Trial initiation date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
3years
TVI-Brain-1 in Expanded Access Patient (clinicaltrials.gov)
P=N/A, Available, TVAX Biomedical
New trial
|
TVI-Brain-1
3years
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma (clinicaltrials.gov)
P2, N=14, Completed, TVAX Biomedical | N=86 --> 14
Enrollment change
|
TVI-Brain-1
over3years
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed o6-methylguanine-DNA-methyltransferase (MGMT) Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2b, N=96, Not yet recruiting, TVAX Biomedical | Initiation date: Mar 2023 --> Jun 2023
Trial initiation date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
over3years
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed o6-methylguanine-DNA-methyltransferase (MGMT) Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2b, N=96, Not yet recruiting, TVAX Biomedical
New P2b trial
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
Share via
